Participation of elderly patients in registration trials for oncology drug applications in Japan

Annals of Oncology

Volumn 21, Issue 10, 2010, Pages 2112-2118

  Yonemori, K ^a,b   Hirakawa, A ^a   Komiyama, N ^a   Kouno, T ^b   Ando, M ^b   Fujiwara, Y ^b   Urano, T ^a   Akagawa, H ^a   Maruyama, H ^a   Toyoshima, S ^a  

^a PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cancer; Clinical trial; Elderly patient; New drug application

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOTOXIC AGENT; MOLECULAR THERAPY AGENT; MONOCLONAL ANTIBODY; NEW DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGISTRY; CONTROLLED STUDY; DATA ANALYSIS; DRUG INDICATION; ELDERLY CARE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PATIENT PARTICIPATION; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREND STUDY;

EID: 77957150298     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq070     Document Type: Article

References (27)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 2000; 50: 7-33.
2. Cabinet Office, Director-General for Policies on Cohesive Society. White paper on Aging Society, Tokyo: Cabinet Office 2009; 2-5.
3. Ford JG, Howerton MW, Lai GY et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 2008; 112: 228-242.
4. Townsley CA, Selby R, Siu LL. Systemic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005; 23: 3112-3124.
5. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer treatment trials. N Engl J Med 1999; 341: 2061-2067.
6. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-1389.
7. Yee KWL, Pater JL, Pho L et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier. J Clin Oncol 2003; 21: 1618-1623.
8. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trial for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004; 22: 4626-4631.
9. Farrell AT, Papadouli I, Hori A et al. The advisory process for anticancer drug regulation: a global perspective. Ann Oncol 2006; 17: 889-896.
10. Hori A, Shibata T, Kami M et al. Age disparity between a cancer population and participants in clinical trials submitted as a new drug application anticancer drugs in Japan. Cancer 2007; 109: 2541-2546.
11. Pharmaceuticals and Medical Devices Agency. Public assessment report http://www.info.pmda.go.jp/shinyaku/shinyaku_index.html (last accessed 20 October 2009).
12. Japan Pharmacists Education Center. Public assessment report http://www.jpec.or.jp/contents/c01/link.html (last accessed 20 October 2009).
13. Nomura K. Cancer Statistics in Japan 2003. Tokyo: Foundation for Promotion Cancer Research 2003.
14. Ministry of Health Labor and Welfare. Annual Report on Health, Labour and Welfare 2003-2004. Tokyo: Gyosei 2004.
15. Surveillance, Epidemiology, and End Results http://seer.cancer.gov (last accessed 20 October 2009).
16. Kornblith AB, Kemeny MM, Peterson BL et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002; 95: 959-996.
17. Lara PN, Higdon R, Lim N et al. Prospective evaluation of cancer clinical trial accrual patterns; identifying potential barriers to enrollment. J Clin Oncol 2001; 19: 1728-1733.
18. Townsley CA, Chan KK, Pond GR et al. Understanding the attitudes of the elderly towards enrollment into cancer clinical trials. BMC Cancer 2006; 6: 34.
19. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
20. Johnson PRE. Acute myeloid leukemia in the elderly: biology and treatment. Br J Haematol 1993; 83: 1-6.
21. Weick JK, Kopecky KJ, Appelbaum FR et al. A randomized investigation of highdose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a southwest oncologist group study. Blood 1996; 88: 2841-2851.
22. Matsumura S, Fukuhara S, Kurokawa K. Nationwide survey of general population for clinical trials. Nihon-Iji-Shinpo 2000; 3962: 14-19 (in Japanese).
23. Ministry of Internal Affairs and Communications. Annual report of current population estimates (as of October 1st, 2008). http://www.e-stat.go.jp/SG1/estat/ListE.do?lid=000001054002 (last accessed 20 October 2009).
24. Ono K, Sugimachi K. The medical care system in Japan. Surgery 2002; 131: 341-342.
25. Morohashi Y. Controversial issues surrounding the case of HIV infections and AIDS through the use of unheated commercial blood products. Jpn Hosp 1997; 16: 1-3.
26. Shibutani Y. A preventive strategy for hepatitis C infection in Kobe city. Official announcement of medical facilities with past fibrinogen administration. Nippon Koshu Eisei Zasshi 2006; 53: 432-436 (in Japanese).
27. Ministry of Health, Labour and Welfare. Guidelines on methods of clinical evaluation of oncology drug Pharmaceutical and Food Safety Bureau Notification, No. 1101001, dated November 1, 2005 (in Japanese).